125 related articles for article (PubMed ID: 9138019)
1. Selective increased presentation of type II collagen by leupeptin.
Manoury-Schwartz B; Chiocchia G; Lotteau V; Fournier C
Int Immunol; 1997 Apr; 9(4):581-9. PubMed ID: 9138019
[TBL] [Abstract][Full Text] [Related]
2. Processing and presentation of type II collagen, a fibrillar autoantigen, by H-2q antigen-presenting cells.
Manoury-Schwartz B; Chiocchia G; Fournier C
Eur J Immunol; 1995 Dec; 25(12):3235-42. PubMed ID: 8566006
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
Hitzel C; van Endert P; Koch N
J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
[TBL] [Abstract][Full Text] [Related]
4. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Qi L; Ostrand-Rosenberg S
Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
[TBL] [Abstract][Full Text] [Related]
5. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system.
Oxenius A; Bachmann MF; Ashton-Rickardt PG; Tonegawa S; Zinkernagel RM; Hengartner H
Eur J Immunol; 1995 Dec; 25(12):3402-11. PubMed ID: 8566030
[TBL] [Abstract][Full Text] [Related]
6. The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules.
Kjellén P; Brunsberg U; Broddefalk J; Hansen B; Vestberg M; Ivarsson I; Engström A; Svejgaard A; Kihlberg J; Fugger L; Holmdahl R
Eur J Immunol; 1998 Feb; 28(2):755-67. PubMed ID: 9521085
[TBL] [Abstract][Full Text] [Related]
7. Antigen processing and presentation of a naturally glycosylated protein elicits major histocompatibility complex class II-restricted, carbohydrate-specific T cells.
Michaëlsson E; Broddefalk J; Engström A; Kihlberg J; Holmdahl R
Eur J Immunol; 1996 Aug; 26(8):1906-10. PubMed ID: 8765038
[TBL] [Abstract][Full Text] [Related]
8. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis.
Myers LK; Rosloniec EF; Seyer JM; Stuart JM; Kang AH
J Immunol; 1993 May; 150(10):4652-8. PubMed ID: 8482852
[TBL] [Abstract][Full Text] [Related]
9. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.
Dang LH; Lien LL; Benacerraf B; Rock KL
J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833
[TBL] [Abstract][Full Text] [Related]
10. Cysteine proteases in Langerhans cells limits presentation of cartilage derived type II collagen for autoreactive T cells.
Holmdahl M; Grubb A; Holmdahl R
Int Immunol; 2004 May; 16(5):717-26. PubMed ID: 15096478
[TBL] [Abstract][Full Text] [Related]
11. MHC class II-restricted presentation of native protein antigen by B cells is inhibitable by cycloheximide and brefeldin A.
St-Pierre Y; Watts TH
J Immunol; 1990 Aug; 145(3):812-8. PubMed ID: 2373860
[TBL] [Abstract][Full Text] [Related]
12. I-Aq and I-Ap bind and present similar antigenic peptides despite differing in their ability to mediate susceptibility to autoimmune arthritis.
Brand DD; Whittington KB; Rosloniec EF
Autoimmunity; 2001; 34(2):133-45. PubMed ID: 11905843
[TBL] [Abstract][Full Text] [Related]
13. The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors.
Vidard L; Rock KL; Benacerraf B
J Immunol; 1991 Sep; 147(6):1786-91. PubMed ID: 1890304
[TBL] [Abstract][Full Text] [Related]
14. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain.
Mizuochi T; Yee ST; Kasai M; Kakiuchi T; Muno D; Kominami E
Immunol Lett; 1994 Dec; 43(3):189-93. PubMed ID: 7721331
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antigen presentation of influenza A nucleoprotein expressed in attenuated AroA- Salmonella typhimurium with that of live virus.
Brett SJ; Rhodes J; Liew FY; Tite JP
J Immunol; 1993 Apr; 150(7):2869-84. PubMed ID: 7681081
[TBL] [Abstract][Full Text] [Related]
16. Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes.
Tran CN; Davis MJ; Tesmer LA; Endres JL; Motyl CD; Smuda C; Somers EC; Chung KC; Urquhart AG; Lundy SK; Kovats S; Fox DA
Arthritis Rheum; 2007 May; 56(5):1497-506. PubMed ID: 17469112
[TBL] [Abstract][Full Text] [Related]
17. The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model.
von Delwig A; Altmann DM; Isaacs JD; Harding CV; Holmdahl R; McKie N; Robinson JH
Arthritis Rheum; 2006 Feb; 54(2):482-91. PubMed ID: 16447222
[TBL] [Abstract][Full Text] [Related]
18. Effects of brefeldin A on cleavage of invariant chain to p21 and p10 and the appearance of Ii-freed class II MHC dimers.
Nguyen QV; Roskey AM; Humphreys RE
Mol Immunol; 1993 Feb; 30(2):137-44. PubMed ID: 8429832
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism in the beta chain of IAq versus IAp influences presentation of protein but not peptide antigens.
Lambert LE; Berling JS; Thompson SD; Harton JA; Bishop GA; Choi E
Cell Immunol; 1995 Oct; 165(2):202-10. PubMed ID: 7553884
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells.
Adorini L; Ullrich SJ; Appella E; Fuchs S
Nature; 1990 Jul; 346(6279):63-6. PubMed ID: 2366863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
